182 related articles for article (PubMed ID: 33108799)
1. Tocilizumab therapy in juvenile systemic sclerosis: a retrospective single centre pilot study.
Adrovic A; Yildiz M; Haslak F; Koker O; Aliyeva A; Sahin S; Barut K; Kasapcopur O
Rheumatol Int; 2021 Jan; 41(1):121-128. PubMed ID: 33108799
[TBL] [Abstract][Full Text] [Related]
2. Add-on tocilizumab versus conventional treatment for systemic sclerosis, and cytokine analysis to identify an endotype to tocilizumab therapy.
Shima Y; Kawaguchi Y; Kuwana M
Mod Rheumatol; 2019 Jan; 29(1):134-139. PubMed ID: 29529897
[TBL] [Abstract][Full Text] [Related]
3. Anti-interleukin 6 Therapy Effect for Refractory Joint and Skin Involvement in Systemic Sclerosis: A Real-world, Single-center Experience.
Panopoulos ST; Tektonidou MG; Bournia VK; Arida A; Sfikakis PP
J Rheumatol; 2022 Jan; 49(1):68-73. PubMed ID: 34393104
[TBL] [Abstract][Full Text] [Related]
4. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial.
Khanna D; Lin CJF; Furst DE; Goldin J; Kim G; Kuwana M; Allanore Y; Matucci-Cerinic M; Distler O; Shima Y; van Laar JM; Spotswood H; Wagner B; Siegel J; Jahreis A; Denton CP;
Lancet Respir Med; 2020 Oct; 8(10):963-974. PubMed ID: 32866440
[TBL] [Abstract][Full Text] [Related]
5. Successful treatment with tocilizumab every 4 weeks of a low disease activity group who achieve a drug-free remission in patients with systemic-onset juvenile idiopathic arthritis.
Kostik MM; Dubko MF; Masalova VV; Snegireva LS; Kornishina TL; Chikova IA; Isupova EA; Kuchinskaya EM; Glebova NI; Buchinskaya NV; Kalashnikova OV; Chasnyk VG
Pediatr Rheumatol Online J; 2015; 13():4. PubMed ID: 25685108
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial.
Khanna D; Denton CP; Jahreis A; van Laar JM; Frech TM; Anderson ME; Baron M; Chung L; Fierlbeck G; Lakshminarayanan S; Allanore Y; Pope JE; Riemekasten G; Steen V; Müller-Ladner U; Lafyatis R; Stifano G; Spotswood H; Chen-Harris H; Dziadek S; Morimoto A; Sornasse T; Siegel J; Furst DE
Lancet; 2016 Jun; 387(10038):2630-2640. PubMed ID: 27156934
[TBL] [Abstract][Full Text] [Related]
7. Expansion of range of joint motion following treatment of systemic sclerosis with tocilizumab.
Shima Y; Hosen N; Hirano T; Arimitsu J; Nishida S; Hagihara K; Narazaki M; Ogata A; Tanaka T; Kishimoto T; Kumanogoh A
Mod Rheumatol; 2015 Jan; 25(1):134-7. PubMed ID: 24533556
[TBL] [Abstract][Full Text] [Related]
8. Effect of mycophenolate mofetil (MMF) on systemic sclerosis-related interstitial lung disease with mildly impaired lung function: a double-blind, placebo-controlled, randomized trial.
Naidu GSRSNK; Sharma SK; Adarsh MB; Dhir V; Sinha A; Dhooria S; Jain S
Rheumatol Int; 2020 Feb; 40(2):207-216. PubMed ID: 31813058
[TBL] [Abstract][Full Text] [Related]
9. Combination therapy with rituximab and mycophenolate mofetil in systemic sclerosis. A single-centre case series study.
Fraticelli P; Fischetti C; Salaffi F; Carotti M; Mattioli M; Pomponio G; Gabrielli A
Clin Exp Rheumatol; 2018; 36 Suppl 113(4):142-145. PubMed ID: 30277864
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of patients with systemic sclerosis treated with tocilizumab: Case series and review of the literature.
Zacay G; Levy Y
Best Pract Res Clin Rheumatol; 2018 Aug; 32(4):563-571. PubMed ID: 31174825
[TBL] [Abstract][Full Text] [Related]
11. Clinical worsening following discontinuation of tocilizumab in diffuse cutaneous systemic sclerosis: a single-centre experience in Japan.
Isomura Y; Shirai Y; Kuwana M
Rheumatology (Oxford); 2022 Nov; 61(11):4491-4496. PubMed ID: 35258561
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate).
Khanna D; Denton CP; Lin CJF; van Laar JM; Frech TM; Anderson ME; Baron M; Chung L; Fierlbeck G; Lakshminarayanan S; Allanore Y; Pope JE; Riemekasten G; Steen V; Müller-Ladner U; Spotswood H; Burke L; Siegel J; Jahreis A; Furst DE
Ann Rheum Dis; 2018 Feb; 77(2):212-220. PubMed ID: 29066464
[TBL] [Abstract][Full Text] [Related]
13. Evidence for Tocilizumab as a Treatment Option in Refractory Uveitis Associated with Juvenile Idiopathic Arthritis.
Tappeiner C; Mesquida M; Adán A; Anton J; Ramanan AV; Carreno E; Mackensen F; Kotaniemi K; de Boer JH; Bou R; de Vicuña CG; Heiligenhaus A
J Rheumatol; 2016 Dec; 43(12):2183-2188. PubMed ID: 27633821
[TBL] [Abstract][Full Text] [Related]
14. Longterm safety and effectiveness of the anti-interleukin 6 receptor monoclonal antibody tocilizumab in patients with systemic juvenile idiopathic arthritis in Japan.
Yokota S; Imagawa T; Mori M; Miyamae T; Takei S; Iwata N; Umebayashi H; Murata T; Miyoshi M; Tomiita M; Nishimoto N; Kishimoto T
J Rheumatol; 2014 Apr; 41(4):759-67. PubMed ID: 24634205
[TBL] [Abstract][Full Text] [Related]
15. Systemic sclerosis: comparison of efficacy of oral cyclophosphamide and azathioprine on skin score and pulmonary involvement-a retrospective study.
Poormoghim H; Rezaei N; Sheidaie Z; Almasi AR; Moradi-Lakeh M; Almasi S; Andalib E
Rheumatol Int; 2014 Dec; 34(12):1691-9. PubMed ID: 24801572
[TBL] [Abstract][Full Text] [Related]
16. Patient satisfaction and clinical effectiveness of switching from intravenous tocilizumab to subcutaneous tocilizumab in patients with juvenile idiopathic arthritis: an observational study.
Ayaz NA; Karadağ ŞG; Koç R; Demirkan FG; Çakmak F; Sönmez HE
Rheumatol Int; 2020 Jul; 40(7):1111-1116. PubMed ID: 32417938
[TBL] [Abstract][Full Text] [Related]
17. A new alternative therapy in dermatology: tocilizumab.
Koryürek ÖM; Kalkan G
Cutan Ocul Toxicol; 2016; 35(2):145-52. PubMed ID: 26023856
[TBL] [Abstract][Full Text] [Related]
18. The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab.
Shima Y; Kuwahara Y; Murota H; Kitaba S; Kawai M; Hirano T; Arimitsu J; Narazaki M; Hagihara K; Ogata A; Katayama I; Kawase I; Kishimoto T; Tanaka T
Rheumatology (Oxford); 2010 Dec; 49(12):2408-12. PubMed ID: 20819796
[TBL] [Abstract][Full Text] [Related]
19. Patient acceptable symptom state in scleroderma: results from the tocilizumab compared with placebo trial in active diffuse cutaneous systemic sclerosis.
Arnold MB; Khanna D; Denton CP; van Laar JM; Frech TM; Anderson ME; Baron M; Chung L; Fierlbeck G; Lakshminarayanan S; Allanore Y; Riemekasten G; Steen V; Müller-Ladner U; Spotswood H; Burke L; Siegel J; Jahreis A; Furst DE; Pope JE
Rheumatology (Oxford); 2018 Jan; 57(1):152-157. PubMed ID: 29077900
[TBL] [Abstract][Full Text] [Related]
20. New developments in juvenile systemic and localized scleroderma.
Foeldvari I
Rheum Dis Clin North Am; 2013 Nov; 39(4):905-20. PubMed ID: 24182860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
